David Segal

机构：North-West University · ORCID：0000-0003-4003-4515

发表论文 62 篇 · 总被引 4156 次 · h-index 27

代表论文

• Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer (2017 · Science Translational Medicine · 被引 192)
• BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival (2019 · Cell Death and Disease · 被引 188)
• Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia (2018 · Leukemia · 被引 175)
• Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo (2017 · Cell Death and Differentiation · 被引 160)
• Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1 (2017 · Leukemia · 被引 155)
• DR5 and caspase-8 are dispensable in ER stress-induced apoptosis (2017 · Cell Death and Differentiation · 被引 92)